Kate Nicholson
Newbury College
2 Papers
Kate Nicholson is an academic researcher from Newbury College. The author has contributed to research in topics: Sorafenib & Hazard ratio. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Riccardo Lencioni,Josep M. Llovet,Guohong Han,Won Young Tak,Jiamei Yang,Alfredo Guglielmi,Seung Woon Paik,Maria Reig,Do Young Kim,Gar Yang Chau,Angelo Luca,Luis Ruiz del Arbol,Marie Aude Leberre,Woody Niu,Kate Nicholson,Gerold Meinhardt,Jordi Bruix +16 more
TL;DR: Sorafenib plus DEB-TACE was technically feasible, but the combination did not improve TTP in a clinically meaningful manner compared with DEB -TACE alone.
646
Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.
Riccardo Lencioni,Josep M. Llovet,Guohong Han,Won Young Tak,Jiamei Yang,MA LeBerre,Woody Niu,Kate Nicholson,Gerold Meinhardt,Jordi Bruix +9 more
TL;DR: The study met its primary endpoint of improving TTP when S was added to a regimen of TACE with DEBDOX, compared with TACEWithDEBDOX alone; the combination was well tolerated; no new safety findings that would preclude use of the combination were observed.
166